![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1392246
¼¼°èÀÇ ³úÁ¾¾ç Áø´Ü ½ÃÀå Á¶»ç º¸°í¼ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)Global Brain Cancer Diagnostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030 |
³úÁ¾¾ç Áø´Ü ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2022³â 25¾ï ´Þ·¯¿¡¼ 2030³â 42¾ï 6,000¸¸ ´Þ·¯¿¡ °¡±î¿î ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2023-2030³â Á¶»ç ±â°£ µ¿¾È 6.9%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³úÁ¾¾ç Áø´ÜÀº ´Ù¾çÇÑ ÀÇ·á ÀýÂ÷, °Ë»ç ¹× ¿µ»ó ±â¼úÀ» ÅëÇØ ³úÁ¾¾ç°ú ¾ÏÀ» ½Äº°, Æò°¡ ¹× ÆÇ´ÜÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áø´ÜÀº ³úÁ¾¾çÀÇ Á¤È®ÇÑ Áø´Ü, Ư¡, À§Ä¡, Å©±â ¹× ¾ÏÀÇ ½É°¢¼ºÀ» ÆÇ´ÜÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
³úÁ¾¾ç Áø´Ü ½ÃÀåÀº ±â¼ú ¹ßÀü, Áúº´ ¹ßº´·ü Áõ°¡, ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ´Ù¾çÇÑ ¿äÀο¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¿µ»ó ±â¼úÀÇ ¹ßÀüÀº º¸´Ù Á¤È®ÇÑ Á¶±â ¹ß°ß ´É·Â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ³úÁ¾¾ç À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß°ú Àû½Ã °³ÀÔÀ» ÃËÁøÇϱâ À§ÇÑ Á¤È®ÇÑ Áø´Ü µµ±¸¿Í ÀýÂ÷¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÎ½Ä °³¼± Ä·ÆäÀΰú °ËÁø ³ë·ÂÀº À§Ç豺¿¡ ´ëÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. »ý°Ë ±â¼ú ¹× À¯ÀüÀÚ °Ë»çÀÇ Çõ½ÅÀº º¸´Ù Á¤È®ÇÑ Á¾¾ç Ư¼º ÆÄ¾Ç¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, °³ÀÎÈµÈ Ä¡·á Á¢±Ù¹ý¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû Áø´Ü ¹æ¹ýÀ» ¼±È£ÇÏ´Â °æÇâÀº ´ú ħ½ÀÀûÀÎ ±â¼ú °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ Áö¿ø, R&D ÀÚ±Ý, Áø´Ü ±â¾÷°ú ÀÇ·á±â°üÀÇ Çù·ÂÀº ±â¼ú Çõ½Å°ú ÷´Ü ³úÁ¾¾ç Áø´Ü ¼Ö·ç¼Ç °³¹ßÀ» ÃËÁøÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ³úÁ¾¾ç Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí Á¶±â ¹ß°ß°ú ¸ÂÃãÇü Ä¡·á Àü·«À» À§ÇÑ º¸´Ù È¿°úÀûÀ̰í ȯÀÚ Ä£ÈÀûÀÎ Áø´Ü µµ±¸ÀÇ Ã¢ÃâÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ³úÁ¾¾ç Áø´Ü ¼¼°è ½ÃÀå¿¡¼ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ³úÁ¾¾ç Áø´Ü »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ ¼½¼Ç¿¡¼´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ³úÁ¾¾ç Áø´Ü ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼´Â ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ÀúÈñ¿¡°Ô ¿¬¶ôÇϽʽÿÀ. ¿ì¸®ÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼¸¦ Á¦°ø ÇÒ ¼ö ÀÖ½À´Ï´Ù.
The global demand for Brain Cancer Diagnostics Market is presumed to reach the market size of nearly USD 4.26 BN by 2030 from USD 2.5 BN in 2022 with a CAGR of 6.9% under the study period 2023 - 2030.
Brain cancer diagnostics involve the identification, assessment, and determination of brain tumors or cancers through various medical procedures, tests, and imaging techniques. These diagnostics are crucial in accurately diagnosing brain tumors, determining their characteristics, location, and size, and grading the cancer's severity.
The brain cancer diagnostics market experiences growth propelled by diverse factors at the intersection of technological advancements, rising disease incidence, and healthcare awareness. Advancements in imaging technologies drive the demand for more precise and early detection capabilities. The increasing prevalence of brain tumors worldwide amplifies the need for accurate diagnostic tools and procedures to facilitate early detection and timely intervention. Heightened awareness campaigns and screening initiatives further drive the demand for diagnostic tests among at-risk populations. Technological innovations in biopsy techniques and genetic testing contribute to more precise tumor characterization, aiding in personalized treatment approaches. Moreover, the preference for non-invasive diagnostic methods fosters the development of less invasive techniques. Government support, research funding, and collaborations between diagnostic firms and healthcare institutions foster innovation and the development of advanced brain cancer diagnostic solutions. Collectively, these factors fuel the growth of the brain cancer diagnostics market, promoting the creation of more effective, patient-friendly diagnostic tools for early detection and tailored treatment strategies.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of brain cancer diagnostics. The growth and trends of brain cancer diagnostics industry provide a holistic approach to this study.
This section of the brain cancer diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Brain Cancer Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Brain Cancer Diagnostics market include GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Rare Diagnostics, Abbott Laboratories, Illumina Inc, Hologic Inc, Agilent Technologies, Bio Rad Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.